The global acquired neuromyotonia treatment market size was valued at USD 14.38 billion in 2025 and is expected to reach USD 21.25 billion by 2033, at a CAGR of 5.00% during the forecast period
The market growth is primarily driven by the increasing prevalence of autoimmune neurological disorders and advancements in diagnostic technologies enabling early and accurate detection of neuromyotonia
Moreover, the rising adoption of immunotherapies, monoclonal antibodies, and plasma exchange treatments, coupled with growing research initiatives to develop targeted therapeutics, is enhancing patient outcomes and accelerating the expansion of the acquired neuromyotonia treatment industry
2 Views